CF BoNT/A

PreclinicalBiologic

MMerz Therapeutics GmbH

CF BoNT/A is one of 22 biologic programs targeting Cervical Dystonia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical DystoniaActive, not recruiting

Cervical DystoniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Cervical Dystonia

#DrugCompanyPhaseTrials

Botox

AbbVie

Approved

3 2

BOTULINUM TOXIN TYPE B

Eisai

Approved

1 3

Dysport

Ipsen

Approved

1 4

Xeomin

MMerz Therapeutics GmbH

Approved

2 5

NT 201

MMerz Pharmaceuticals GmbH

Approved

1 6

XEOMIN

MMerz Pharmaceuticals GmbH

Phase 3

1 7

Ingrezza

Neurocrine Biosciences

Phase 2

1 8

Marinol

Alnylam Pharmaceuticals

Phase 2

1 9

Meditoxin

MMedy-Tox

Phase 3

2 10

Fycompa

CCatalyst Biosciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cervical Dystonia1 trial

Assessment of Long-term Clinical Response to BoNT in Cervical Dystonia

Completed·MMerz Therapeutics GmbH··NCT05884528·270 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CF BoNT/A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CF BoNT/A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CF BoNT/A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merz Therapeutics GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: MMerz Therapeutics GmbH

CF BoNT/A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cervical Dystonia1 trial

References

Drug Info

Quick Facts

Related News